会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • MATRIX METALLOPROTEINASE INHIBITORS
    • 基质金属蛋白酶抑制剂
    • WO2005016868A3
    • 2005-05-19
    • PCT/EP2004009087
    • 2004-08-12
    • GLAXO GROUP LTDHOLMES IANWATSON STEPHEN PAUL
    • HOLMES IANWATSON STEPHEN PAUL
    • C07C233/51C07C235/34C07C235/78C07C255/57C07D209/08C07D333/24C07C235/00C07C255/00
    • C07C235/78C07C233/51C07C235/34C07C255/57C07C2601/14C07D209/08C07D333/24
    • Compounds of Formula (I), wherein R represents optionally substituted -C4-12 alkyl, -C2-10alkylcycloalkyl, -C2-6 alkyl heterocycloalkyl, -C2-6alkylaryl, optionally substituted 5- or 6- membered aryl or heteroaryl, except pyridinyl. Z represents a bond, CH2, O, S, SO, SO2, NR , OCR R , CR R O, or Z, R and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6- membered aryl or heteroaryl ring; X represents COR ; R represents CONH2, CO2H, CO2R , SO2R or SO2NR R , except that R ; may not represent CO2R when X is CONH2 ; R represents OR , or NR R ; R and R each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R represents H or C1-6 alkyl; R represents C1-6 alkyl; R and R each independently represents H or C1-6 alkyl or R and R together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; and physiologically functional derivatives thereof with the exception of [3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid and 3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid diethyl ether; butanedioic acid [3-methoxy-4-(phenylmethoxy)phenyl]; butanedioic acid [4-(phenylmethoxy)phenyl]; with the proviso that when R represents C4-12 alkyl, Z is other than a bond, O or CH2; and physiologically functional derivatives thereof , processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs) are described.
    • 式(I)化合物,其中R 1表示任选取代的-C 4-12烷基,-C 2-10烷基环烷基,-C 2-6烷基杂环烷基,-C 2-6烷基芳基,任选取代的5-或6-元芳基或杂芳基, 除了吡啶基。 Z表示键,CH 2,O,S,SO,SO 2,NR 4,OCR 4 R 5,CR 4 R 5 O或Z,R 1和Q一起形成 任选取代的稠合三环基团; Q代表任选取代的5元或6元芳基或杂芳基环; X代表COR 3; R 2代表CONH 2,CO 2 H,CO 2 R 7,SO 2 R 7或SO 2 NR 8 R 9,除了R 2; 当X是CONH 2时可能不代表CO 2 R 7; R 3表示OR 6或NR 8 R 9; R 4和R 5各自独立地表示H,C 1-6烷基或C 1-4烷基芳基; R6代表H或C1-6烷基; R 7表示C 1-6烷基; R 8和R 9各自独立地表示H或C 1-6烷基或者R 8和R 9与它们所连接的氮原子一起形成5-或6-元环,其可任选地 包括1个或多个选自O,S和N的其他杂原子; 以及除[3-(乙酰氨基)-4-环己基苯基] - 丁二酸和3-(乙酰氨基)-4-环己基苯基] - 丁二酸二乙酯以外的其生理学功能衍生物; 丁二酸[3-甲氧基-4-(苯基甲氧基)苯基]; 丁二酸[4-(苯基甲氧基)苯基]; 条件是当R 1代表C 4-12烷基时,Z不是键,O或CH 2; 及其生理功能衍生物,其制备方法,含有它们的药物制剂以及它们作为基质金属蛋白酶(MMP)抑制剂的用途。
    • 7. 发明专利
    • AT413384T
    • 2008-11-15
    • AT04765231
    • 2004-09-10
    • GLAXO GROUP LTD
    • GAINES SIMONHOLMES IANMARTIN STEPHENWATSON STEPHEN
    • C07D209/48A61K31/4035A61K31/505A61K31/506A61P29/00C07D239/54C07D403/10C07D405/10
    • Compounds of Formula (I): Wherein: A represents bond, C 1-6 alkyl or CH=CH-C 1-4 alkyl; B represents bond, O, S, SO, SO 2 , CO, CR 7 R 8 , CO 2 R 14 , CONR 14 R 15 , N(COR 14 )(COR 15 ), N(SO 2 R 14 )(COR 15 ) or NR 14 R 15 ; D represents bond, or C 1-6 alkyl; E represents substituted aryl or substituted or unsubstituted heteroaryl; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents O, S, SO, SO 2 , CO, CNR 5 , CNOR 5 , CNNR 5 R 6 , NR 11 or CR 7 R 8 ; Y represents CR 5 OR 11 , CR 5 SR 11 , NOR 5 , CR 5 NR 6 R 11 , SO, SO 2 , CO, CNR 5 , CNOR 5 or CS; R 1 and R 1' each independently represents H, C 1-6 alkyl or C 1-4 alkylaryl; R 2 represents CO 2 R 12 , CH 2 OR 12 or CONR 12 R 13 , CONR 12 OR 13 , NR 12 COR 13 , SR 12 , PO(OH) 2 , PONHR 12 or SONHR 12 ; R 3 represents H, C 1-6 alkyl or C 1-4 alkylaryl; R 4 represents optionally substituted aryl or heteroaryl; Z represents a bond, CH 2 , O, S, SO, SO 2 , NR 5 , OCR 5 R 6 , CR 9 R 10 O or Z, R 4 and Q together form an optionally substituted fused tricyclic group; R 5 and R 6 each independently represent H, C 1-6 alkyl or C 1-4 alkylaryl; R 7 and R 8 each independently represent H, halo, C 1-6 alkyl or C 1-4 alkylaryl; R 9 and R 10 each independently represents H, C 1-6 alkyl optionally substituted by halo, cyano, OR 11 or NR 6 R 11 , C 1-4 alkylaryl optionally substituted by halo, cyano, OR11 or NR 6 R 11 , OR 11 or, together with the N to which they are attached, R 9 and R 10 form a heterocyclic group: R 11 represents H, C 1-6 alkyl, C 1-4 alkylaryl or COR 5 ; R 12 and R 13 each independently represent H, C 1-3 alkyl, C 1-3 alkylaryl or C 1-3 alkylheteroaryl or, together with the functionality to which they are attached, R 12 and R 13 form a heterocyclic group: R 14 and R 15 each independently represent H, C 1-6 alkyl, C 1-4 alkylaryl or C 1-4 alkylheteroaryl or together with the functionality to which they are attached R 14 and R 15 form a heterocyclic or fused heterocyclic group: and physiologically functional derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs) are described.